{"title":"Hepatocellular carcinoma converted from atezolizumab and bevacizumab combination therapy: a case report.","authors":"Keisuke Ida, Satoshi Koizumi, Atsuhito Tsuchihashi, Shinjiro Kobayashi, Takehito Otsubo","doi":"10.1093/omcr/omae155","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatectomy is the curative treatment for hepatocellular carcinoma (HCC), with targeted therapy used when resection is difficult. In this rare case, the tumor shrank with targeted therapy, enabling radical treatment through conversion surgery. The patient, a man in his 70s, developed an 11.5-cm HCC (T3N0M0 Stage III) in the posterior hepatic zone after being virologically negative for hepatitis C. The tumor was near the right portal vein branch, making the liver lobe unresectable due to poor liver function. Upon tumor enlargement, he was treated with atezolizumab and bevacizumab. After 5 courses, the tumor significantly shrank, allowing for complete resection with posterior segment removal. The surgery revealed mostly necrotic tumors with no active cancer cells remaining.</p>","PeriodicalId":45318,"journal":{"name":"Oxford Medical Case Reports","volume":"2024 12","pages":"omae155"},"PeriodicalIF":0.5000,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11682486/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oxford Medical Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/omcr/omae155","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Hepatectomy is the curative treatment for hepatocellular carcinoma (HCC), with targeted therapy used when resection is difficult. In this rare case, the tumor shrank with targeted therapy, enabling radical treatment through conversion surgery. The patient, a man in his 70s, developed an 11.5-cm HCC (T3N0M0 Stage III) in the posterior hepatic zone after being virologically negative for hepatitis C. The tumor was near the right portal vein branch, making the liver lobe unresectable due to poor liver function. Upon tumor enlargement, he was treated with atezolizumab and bevacizumab. After 5 courses, the tumor significantly shrank, allowing for complete resection with posterior segment removal. The surgery revealed mostly necrotic tumors with no active cancer cells remaining.
期刊介绍：
Oxford Medical Case Reports (OMCR) is an open access, peer-reviewed online journal publishing original and educationally valuable case reports that expand the field of medicine. The journal covers all medical specialities including cardiology, rheumatology, nephrology, oncology, neurology, and reproduction, comprising a comprehensive resource for physicians in all fields and at all stages of training. Oxford Medical Case Reports deposits all articles in PubMed Central (PMC). Physicians and researchers can find your work through PubMed , helping you reach the widest possible audience. The journal is also indexed in the Web of Science Core Collection . Oxford Medical Case Reports publishes case reports under the following categories: Allergy Audiovestibular medicine Cardiology and cardiovascular systems Critical care medicine Dermatology Emergency medicine Endocrinology and metabolism Gastroenterology and hepatology Geriatrics and gerontology Haematology Immunology Infectious diseases and tropical medicine Medical disorders in pregnancy Medical ophthalmology Nephrology Neurology Oncology Paediatrics Pain Palliative medicine Pharmacology and pharmacy Psychiatry Radiology, nuclear medicine, and medical imaging Respiratory disorders Rheumatology Sexual and reproductive health Sports Medicine Substance abuse.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
